{
    "organizations": [],
    "uuid": "6a62a0a8560885a22116701348d0f44b2f3a8f3a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-psividas-second-phase-3-study-for/brief-psividas-second-phase-3-study-for-durasert-three-year-treatment-for-posterior-segment-uveitis-maintains-positive-efficacy-and-safety-profile-at-12-months-idUSFWN1PX1JP",
    "ord_in_thread": 0,
    "title": "BRIEF-Psivida's Second Phase 3 Study For Durasert Three-Year Treatment For Posterior Segment Uveitis Maintains Positive Efficacy And Safety Profile At 12 Months",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 7 (Reuters) - Psivida Corp:\n* PSIVIDA‘S SECOND PHASE 3 STUDY FOR DURASERT™ THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS MAINTAINS POSITIVE EFFICACY AND SAFETY PROFILE AT 12 MONTHS\n* PSIVIDA CORP - HIGHLY SIGNIFICANT DIFFERENCE BETWEEN DURASERT AND SHAM IN PREVENTION OF UVEITIS RECURRENCE AT 12 MONTHS IN STUDY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-08T05:51:00.000+02:00",
    "crawled": "2018-02-09T06:07:40.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "psivida",
        "corp",
        "psivida",
        "second",
        "phase",
        "study",
        "treatment",
        "posterior",
        "segment",
        "uveitis",
        "maintains",
        "positive",
        "efficacy",
        "safety",
        "profile",
        "month",
        "psivida",
        "corp",
        "highly",
        "significant",
        "difference",
        "durasert",
        "sham",
        "prevention",
        "uveitis",
        "recurrence",
        "month",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}